SoluBest, Ltd, today announced an agreement to license its proprietary nanotechnology platform for significantly improving the bio-performance of poorly soluble and insoluble drugs to CoreRx, Inc., an innovative contract formulation company. SoluBest’s Solumer™ technology is extremely versatile, as it can be applied to a wide range of pharmaceuticals. The license agreement will provide CoreRx with access to Solumer™ technology and the rights to apply the technology to client’s drug candidates currently in clinical development.

“We are excited at the opportunity to enhance our contract drug development offerings through the Solumer™ technology,” said Todd R. Daviau, CEO of CoreRx. “Since the beginning, CoreRx has been working to meet the increasing formulation development challenges of drug delivery, as well as performance enhancement of our client’s drug products.  As companies continue to outsource development, speed, quality, and innovation become increasingly important to our contract lab offerings. (more…)